Guidelines for Human Embryonic and Induced Pluripotent Stem Cells
The use of Human Embryonic Stem Cells (hESCs), which are subject to strict oversight, and Human Induced Pluripotent Stem Cell (iPSC) lines are considered major research tools by the Office of Intramural Research (OIR).
Guidelines for acquisition of Human iPS and ES cell lines can be found at:
If you are using, making, or planning to acquire either hESCs or iPSCs please submit the following information by email to Kathryn Partin, AIRIO:
- A completed and signed copy of the registration form or checklist for the cell line(s) you will be using:
- Acquisition of iPSCs must be reviewed and approved by an IRB if the line has not been anonymized. A copy of the approval must be attached to the checklist.
- If hESC or iPSC lines are purchased from or made by a commercial source or obtained from an outside collaborator, contact the Technology Transfer Office or your Technology Development Coordinator. A copy of the MTA agreement should also be included.
- iPSCs made by a NIH Core facility (e.g., NHLBI) may also require an MTA for transfer of cells to you. This is for tracking purposes.
- Derivation of iPSCs from patient, volunteer, or samples collected at NIH and held in our repository, when linked to identifiers accessible to the NIH investigator, must have IRB approval. Provide an approved IRB protocol number in addition to the other documents.
- All iPSCs that are generated within the IRP or under contract to be used for in vitro experiments or in animals using recombinant DNA technology must also be reviewed and approved by the Institutional Biosafety Committee. The cells you will get back may be considered recombinant materials and need to be registered. Include the IBC number and approval/registration date. If you have any questions contact the Institutional Biosafety Officer, Richard Baumann (301-496-2960).
Kathryn M. Partin, Ph.D.
Director of Research Integrity
NIH Agency Intramural Research Integrity Officer (AIRIO)
The page was last updated on Wednesday, July 31, 2019 - 12:06pm